EGFR and non-small cell lung carcinoma: On the other hand, given the demonstrated overall survival benefit and the approval of osimertinib as adjuvant treatment for patients with early-stage NSCLC harboring an epidermal growth factor receptor (EGFR) mutation, it was considered that the presence of this mutation should always be evaluated at diagnosis in patients with locally advanced disease to guide treatment [35, 36].